Andere Sprachen WuXi Biologics (Cayman) Inc.

Aktien

A2QJCN

KYG970081173

2269

Biotechnologie

Markt geschlossen - Hong Kong S.E. Andere Börsenplätze 09:08:35 15.12.2025			% 5 Tage	Veränd. 1. Jan.
32.44 ^HKD	-3.11%		-0.55%	+84.74%

02.12.	WuXi Biologics erweitert globales CRDMO-Netzwerk nach Katar durch strategisches Memorandum mit der Qatar Free Zones Authority	CI
28.11.	WUXI BIOLOGICS (CAYMAN) INC. : Nomura bleibt bei seiner Kaufempfehlung	ZM

Andere Sprachen

Chinese biologics giant WuXi inks MoU with Qatar Free Zones to launch first Middle East CRDMO hub	02.12.
Wuxi Biologics Extends Global CRDMO Network to Qatar Through Strategic MOU Signed with Qatar Free Zones Authority	02.12.
WuXi Biologics Extends Global CRDMO Network to Qatar Through Strategic MoU Signed with Qatar Free Zones Authority	02.12.
WuXi Biologics Cayman : Extends Global CRDMO Network to Qatar Through Strategic MoU Signed with Qatar Free Zones Authority	02.12.
WuXi accelerating biologics with TrueSite TI	29.10.
WuXi XDC Completes HK$1.4 Billion Share Sale to WuXi Biologics	23.10.
WuXi Biologics Included in Hang Seng Corporate Sustainability Benchmark Index	22.10.
WuXi Biologics Honored with 2025 Global Customer Value Leadership Recognition by Frost & Sullivan	20.10.
BlackRock Inc's long position in Wuxi Biologics increases to 5.43% on Oct 10, HKEX filing shows	15.10.
WuXi Biologics Receives MSCI AAA ESG Rating for Third Consecutive Year	13.10.
HKEX says BlackRock's long position in Wuxi Biologics (Cayman) decreases to 4.99%	10.10.
WuXi Biologics Receives MSCI AAA ESG Rating for Third Consecutive Year	10.10.
WuXi Biologics Launches WuXia4.0, Targeted Integration Cell Line Platform TrueSite TI,to Accelerate Biologics Development with High Titer and Superior Stability	26.09.
WuXi Biologics Cayman : Launches WuXia™4.0, Targeted Integration Cell Line Platform TrueSite TI™，to Accelerate Biologics Development with High Titer and Superior Stability	26.09.
WuXi Biologics Launches WuXia 4.0, Targeted Integration Cell Line Platform TrueSite TI, to Accelerate Biologics Development with High Titer and Superior Stability	25.09.
WuXi Biologics Selected as Constituent of FTSE4Good Index Series for Fifth Consecutive Year	23.09.
WuXi XDC Cayman Revises Caps, Renews Service Agreements With WuXi Biologics	23.09.
WuXi Biologics Cayman : Selected as Constituent of FTSE4Good Index Series for Fifth Consecutive Year	23.09.
Three WuXi Biologics Manufacturing Facilities Receive GMP Certification from Türkiye İlaç ve Tıbbi Cihaz Kurumu (TITCK)	17.09.
WuXi Biologics Cayman : Three WuXi Biologics Manufacturing Facilities Receive GMP Certification from Türkiye İlaç ve Tıbbi Cihaz Kurumu (TITCK)	17.09.
WuXi Biologics Achieves 'CDMO of the Year' Among Three Prestigious IMAPAC Awards	12.09.
WuXi Biologics Achieves "CDMO of the Year" Among Three Prestigious IMAPAC Awards	12.09.
Chinese Pharma Stocks Fall on Potential U.S. Restrictions on Drugs	11.09.
WuXi Biologics Launches Green CRDMO White Paper to Advance Sustainability in Biologics Industry	09.09.
WuXi Biologics launches green CRDMO white paper to advance sustainability in biologics industry	09.09.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen WuXi Biologics (Cayman) Inc.

Aktien

A2QJCN

KYG970081173

2269

Biotechnologie

Andere Sprachen

Filter